2014-11-26 23:03:10 UTC

CGH Podcast November 2014: Mesalamine Dosage and Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis

A study in the November issue of CGH investigated whether increasing doses of mesalamine reduces concentrations of fecal calprotectin in patients with quiescent ulcerative colitis. Dr. Kuemmerle speaks to co-author Dr. James Lewis of the Perelman School of Medicine at the University of Pennsylvania; Plus, summaries of top stories from this month's issue of GI and Hepatology News.

 

 

Osterman MT, Aberra FN, Cross R. Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis. Clinical Gastroenterology & Hepatology 2014; November 12(11): 1887–1893.e3
Abstract

 

 

 

Duration: 15.20m
Filetype: mp3
Bitrate: 96 KBPS
Frequency: 44100 HZ

 

 

More on Ulcerative Colitis

Digestive Disease Week® (DDW)

May 6, 2017

Digestive Disease Week® (DDW) is the premier meeting for the GI professional. Every year it attracts approximately 15,000 physicians, researchers and academics from around the world who desire to stay up-to-date in the field.

Announcing New Crohn’s & Colitis Congress

March 9, 2017

AGA and the Crohn’s & Colitis Foundation are joining together to put on a must-attend IBD conference January 2018 in Las Vegas.

AGA and Crohn’s & Colitis Foundation Announce Conference Partnership

March 9, 2017

Inaugural Crohn’s & Colitis Congress for health-care professionals and researchers to take place in Las Vegas in January 2018.